Kiora Pharmaceuticals Key Executives
This section highlights Kiora Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Kiora Pharmaceuticals
(Showing 0 of )
Kiora Pharmaceuticals Earnings
This section highlights Kiora Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
$3.20
Stock Price
$9.60M
Market Cap
12
Employees
Salt Lake City, UT
Location
Financial Statements
Access annual & quarterly financial statements for Kiora Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $16.02M | $- | $- | $- | $12.06K |
| Cost of Revenue | $- | $4.03M | $134.03K | $227.27K | $200.22K |
| Gross Profit | $16.02M | $-4.03M | $-134.03K | $-227.27K | $-188.16K |
| Gross Profit Ratio | 100.00% | - | - | - | -1560.34% |
| Research and Development Expenses | $7.84M | $4.03M | $3.45M | $5.35M | $3.57M |
| General and Administrative Expenses | $5.54M | $4.66M | $8.28M | $5.32M | $4.66M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.54M | $4.66M | $8.28M | $5.32M | $4.66M |
| Other Expenses | $-1.89M | $-130.32K | $582.61K | $6.27M | $- |
| Operating Expenses | $11.49M | $8.56M | $11.73M | $10.67M | $8.22M |
| Cost and Expenses | $11.49M | $12.59M | $11.73M | $10.67M | $8.22M |
| Interest Income | $1.25M | $173.99K | $56.89K | $1.14K | $23.34K |
| Interest Expense | $21.45K | $11.13K | $8.60K | $6.85K | $4.19K |
| Depreciation and Amortization | $19.20K | $62.42K | $134.03K | $227.27K | $200.22K |
| EBITDA | $5.70M | $-12.35M | $-13.55M | $-13.73M | $-6.65M |
| EBITDA Ratio | 35.58% | - | - | - | -55106.60% |
| Operating Income | $4.51M | $-12.59M | $-12.31M | $-16.94M | $-8.19M |
| Operating Income Ratio | 28.15% | - | - | - | -67911.24% |
| Total Other Income Expenses Net | $1.15M | $163.32K | $-1.39M | $272.48K | $19.15K |
| Income Before Tax | $5.66M | $-12.42M | $-13.70M | $-16.70M | $-8.08M |
| Income Before Tax Ratio | 35.33% | - | - | - | -67002.94% |
| Income Tax Expense | $2.07M | $90.32K | $-113.01K | $-304.78K | $12.05K |
| Net Income | $3.59M | $-12.51M | $-13.58M | $-16.39M | $-8.09M |
| Net Income Ratio | 22.44% | - | - | - | -67102.91% |
| EPS | $0.93 | $-24.25 | $-18.55 | $-68.00 | $-70.50 |
| EPS Diluted | $0.87 | $-24.25 | $-18.55 | $-68.00 | $-70.50 |
| Weighted Average Shares Outstanding | 3.87M | 538.01K | 732.30K | 241.10K | 114.79K |
| Weighted Average Shares Outstanding Diluted | 4.13M | 538.01K | 732.30K | 241.10K | 114.79K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $20.00K | $16.00M | $283.87K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $12.06K | $- | $- | $- |
| Cost of Revenue | $15.99M | $- | $17.88K | $16.21K | $7.93K | $42.38K | $56.70K | $42.86K | $10.29K | $36.60K | $567.23K | $61.88K | $59.50K | $58.18K | $59.50K | $50.09K | $717.62K | $985.88K | $631.11K | $938.04K |
| Gross Profit | $-15.99M | $- | $2.12K | $15.98M | $275.94K | $-42.38K | $-56.70K | $-42.86K | $-10.29K | $-36.60K | $-567.23K | $-61.88K | $-59.50K | $-58.18K | $-59.50K | $-50.09K | $-705.56K | $-985.88K | $-631.11K | $-938.04K |
| Gross Profit Ratio | - | 0.00% | 10.62% | 99.90% | 97.20% | - | - | - | - | - | - | - | - | - | - | - | -5850.87% | - | - | - |
| Research and Development Expenses | $4.12M | $1.32M | $906.68K | $1.49M | $1.11M | $1.09M | $1.39M | $438.28K | $841.62K | $1.33M | $567.23K | $707.93K | $1.00M | $1.63M | $1.44M | $1.28M | $1.01M | $985.88K | $631.11K | $938.04K |
| General and Administrative Expenses | $1.33M | $1.38M | $1.54M | $1.30M | $880.55K | $1.42M | $1.10M | $1.27M | $2.78M | $2.03M | $1.80M | $1.66M | $1.38M | $1.34M | $1.31M | $1.30M | $1.51M | $1.02M | $1.09M | $1.03M |
| Selling and Marketing Expenses | $34.09K | $- | $-17.88K | $-16.21K | $-7.93K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.36M | $1.38M | $1.52M | $1.28M | $872.62K | $1.42M | $1.10M | $1.27M | $2.78M | $2.03M | $1.80M | $1.66M | $1.38M | $1.34M | $1.31M | $1.30M | $1.51M | $1.02M | $1.09M | $1.03M |
| Other Expenses | $-2.89M | $904.01K | $-18.86K | $8.07K | $-65.65K | $105.72K | $-25.89K | $14.67K | $245.09K | $937 | $32.94K | $1.20M | $6.27M | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $2.56M | $3.60M | $2.43M | $2.77M | $1.98M | $2.50M | $2.49M | $1.71M | $3.62M | $3.37M | $2.37M | $2.37M | $2.38M | $2.97M | $2.75M | $2.58M | $2.53M | $2.01M | $1.72M | $1.97M |
| Cost and Expenses | $2.56M | $3.60M | $2.44M | $2.79M | $1.99M | $2.50M | $2.49M | $1.71M | $3.62M | $3.37M | $2.37M | $2.37M | $2.38M | $2.97M | $2.75M | $2.58M | $2.53M | $2.01M | $1.72M | $1.97M |
| Interest Income | $438.86K | $248.84K | $342.10K | $223.05K | $45.52K | $49.91K | $45.09K | $33.47K | $56.89K | $7.86K | $1.24K | $217 | $300 | $259 | $332 | $250 | $224 | $331 | $4.34K | $18.44K |
| Interest Expense | $21.45K | $- | $- | $- | $37.00K | $- | $- | $- | $738 | $7.86K | $- | $217 | $4.13K | $- | $2.03K | $686 | $4.19K | $- | $- | $- |
| Depreciation and Amortization | $5.91K | $2.10K | $17.88K | $16.21K | $7.93K | $42.38K | $56.70K | $42.86K | $10.29K | $36.60K | $46.42K | $61.88K | $59.50K | $58.18K | $59.50K | $50.09K | $9.06K | $8.64K | $8.64K | $7.07K |
| EBITDA | $-2.40M | $-2.70M | $-2.42M | $13.47M | $-6.78M | $-2.49M | $-2.47M | $-1.70M | $-2.60M | $-3.36M | $-2.35M | $-2.36M | $-5.88M | $-2.96M | $-2.41M | $-2.53M | $-2.43M | $-2.00M | $-1.71M | $-1.96M |
| EBITDA Ratio | - | - | -12091.62% | 84.18% | -2388.74% | - | - | - | - | - | - | - | - | - | - | - | -20169.49% | - | - | - |
| Operating Income | $-2.56M | $-3.60M | $-2.42M | $13.21M | $-1.99M | $-5.92M | $-2.63M | $-1.92M | $-2.63M | $-3.70M | $-2.40M | $-3.57M | $-8.65M | $-2.97M | $-2.75M | $-2.58M | $-2.51M | $-2.01M | $-1.72M | $-1.97M |
| Operating Income Ratio | - | - | -12123.25% | 82.56% | -701.80% | - | - | - | - | - | - | - | - | - | - | - | -20843.06% | - | - | - |
| Total Other Income Expenses Net | $406.19K | $188.91K | $323.24K | $243.31K | $-59.64K | $155.63K | $19.20K | $48.13K | $23.54K | $-1.42M | $1.24K | $4.43K | $424.65K | $68.27K | $350.21K | $-570.64K | $109.75K | $331 | $4.34K | $18.44K |
| Income Before Tax | $-2.16M | $-3.41M | $-2.22M | $13.45M | $-2.18M | $-5.76M | $-2.61M | $-1.87M | $-2.61M | $-5.12M | $-2.40M | $-3.57M | $-8.68M | $-2.97M | $-2.47M | $-2.58M | $-2.40M | $-2.01M | $-1.72M | $-1.95M |
| Income Before Tax Ratio | - | - | -11108.23% | 84.08% | -767.35% | - | - | - | - | - | - | - | - | - | - | - | -19932.91% | - | - | - |
| Income Tax Expense | $2.07M | $- | $3 | $-2 | $90.32K | $3.37M | $98.53K | $369.72K | $113.01K | $1.42M | $-36.14K | $-4.43K | $304.78K | $259 | $2.03K | $250 | $12.05K | $331 | $4.34K | $18.44K |
| Net Income | $-4.22M | $-3.41M | $-2.22M | $13.45M | $-2.27M | $-5.76M | $-2.61M | $-2.24M | $-2.72M | $-6.54M | $-2.40M | $-3.56M | $-8.38M | $-2.97M | $-2.47M | $-2.58M | $-2.42M | $-2.01M | $-1.72M | $-1.95M |
| Net Income Ratio | - | - | -11108.23% | 84.08% | -799.17% | - | - | - | - | - | - | - | - | - | - | - | -20032.88% | - | - | - |
| EPS | $-1.09 | $-0.81 | $-0.53 | $0.52 | $-0.29 | $-0.81 | $-0.79 | $-1.20 | $-1.52 | $-7.70 | $-7.35 | $-11.25 | $-32.65 | $-11.56 | $-13.23 | $-14.03 | $-21.25 | $-17.65 | $-15.13 | $-17.26 |
| EPS Diluted | $-1.02 | $-0.81 | $-0.53 | $0.38 | $-0.29 | $-0.81 | $-0.79 | $-1.20 | $-1.52 | $-7.70 | $-7.35 | $-10.91 | $-32.65 | $-11.09 | $-13.23 | $-14.03 | $-21.25 | $-17.65 | $-15.13 | $-17.26 |
| Weighted Average Shares Outstanding | 3.87M | 4.21M | 4.17M | 25.94M | 7.71M | 7.11M | 3.29M | 1.86M | 1.80M | 848.53K | 326.64K | 316.38K | 256.63K | 256.63K | 186.66K | 183.95K | 113.69K | 113.69K | 113.49K | 113.12K |
| Weighted Average Shares Outstanding Diluted | 4.13M | 4.21M | 4.17M | 35.03M | 7.71M | 7.11M | 3.29M | 1.86M | 1.80M | 848.53K | 326.64K | 326.46K | 256.63K | 267.59K | 186.66K | 183.95K | 113.69K | 113.69K | 113.49K | 113.12K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.79M | $2.45M | $5.96M | $7.85M | $1.19M |
| Short Term Investments | $23.00M | $- | $- | $- | $- |
| Cash and Short Term Investments | $26.79M | $2.45M | $5.96M | $7.85M | $1.19M |
| Net Receivables | $871.44K | $2.05M | $1.37M | $529.56K | $90.97K |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $2.04M | $233.38K | $343.07K | $1.21M | $449.57K |
| Total Current Assets | $29.71M | $4.74M | $7.68M | $8.99M | $1.81M |
| Property Plant Equipment Net | $62.40K | $114.95K | $172.17K | $283.41K | $30.57K |
| Goodwill | $- | $- | $- | $- | $3.48M |
| Intangible Assets | $6.69M | $8.81M | $10.74M | $8.70M | $9.73M |
| Goodwill and Intangible Assets | $6.69M | $8.81M | $10.74M | $8.70M | $13.21M |
| Long Term Investments | $- | $- | $49.26K | $45.00K | $45.00K |
| Tax Assets | $- | $- | $-49.26K | $-45.00K | $-45.00K |
| Other Non-Current Assets | $28.97K | $45.03K | $82.26K | $87.96K | $102.07K |
| Total Non-Current Assets | $6.78M | $8.97M | $11.00M | $9.07M | $13.35M |
| Other Assets | $- | $1 | $0 | $0 | $0 |
| Total Assets | $36.48M | $13.71M | $18.68M | $18.06M | $15.16M |
| Account Payables | $415.59K | $206.26K | $1.01M | $160.62K | $434.76K |
| Short Term Debt | $23.36K | $47.07K | $211.56K | $237.69K | $260.58K |
| Tax Payables | $2.33M | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $3.24M | $1.38M | $2.05M | $1.21M | $1.29M |
| Total Current Liabilities | $6.01M | $1.63M | $3.27M | $1.61M | $1.77M |
| Long Term Debt | $33.81K | $59.82K | $- | $90.57K | $313.81K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $490.69K | $779.44K | $689.12K | $614.44K | $728.93K |
| Other Non-Current Liabilities | $4.19M | $5.13M | $3.31M | $3.85M | $2.55M |
| Total Non-Current Liabilities | $4.72M | $5.97M | $4.00M | $7.22M | $6.39M |
| Other Liabilities | $- | $- | $0 | $- | $- |
| Total Liabilities | $10.72M | $7.60M | $7.27M | $8.83M | $8.16M |
| Preferred Stock | $4 | $4 | $- | $- | $41 |
| Common Stock | $267.68K | $77.08K | $17.99K | $126.64K | $55.56K |
| Retained Earnings | $-143.38M | $-146.98M | $-134.46M | $-124.73M | $-108.34M |
| Accumulated Other Comprehensive Income Loss | $-282.16K | $-182.80K | $-182.74K | $-86.43K | $-802 |
| Other Total Stockholders Equity | $169.16M | $153.19M | $146.04M | $135.42M | $116.78M |
| Total Stockholders Equity | $25.76M | $6.11M | $11.41M | $9.22M | $7.00M |
| Total Equity | $25.76M | $6.11M | $11.41M | $9.22M | $7.00M |
| Total Liabilities and Stockholders Equity | $36.48M | $13.71M | $18.68M | $18.06M | $15.16M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $36.48M | $13.71M | $18.68M | $18.06M | $15.16M |
| Total Investments | $23.00M | $4.27K | $49.26K | $45.00K | $45.00K |
| Total Debt | $57.17K | $106.89K | $105.78K | $209.41K | $362.12K |
| Net Debt | $-3.74M | $-2.35M | $-5.86M | $-7.65M | $-823.56K |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.79M | $5.64M | $6.58M | $31.28M | $2.45M | $5.40M | $7.95M | $3.43M | $5.96M | $4.80M | $2.43M | $5.07M | $7.85M | $11.11M | $3.66M | $6.61M | $1.19M | $2.93M | $4.69M | $5.88M |
| Short Term Investments | $23.00M | $23.40M | $21.24M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $26.79M | $29.04M | $27.82M | $31.28M | $2.45M | $5.40M | $7.95M | $3.43M | $5.96M | $4.80M | $2.43M | $5.07M | $7.85M | $11.11M | $3.66M | $6.61M | $1.19M | $2.93M | $4.69M | $5.88M |
| Net Receivables | $871.44K | $1.78M | $3.67M | $2.00M | $2.05M | $1.34M | $804.51K | $1.70M | $1.37M | $1.56M | $552.95K | $552.24K | $529.56K | $421.46K | $311.17K | $147.10K | $90.97K | $2.77K | $1.52K | $5.34K |
| Inventory | $- | $- | $- | $1 | $1 | $166.23K | $198.66K | $400.05K | $- | $134.38K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $2.04M | $834.13K | $195.82K | $206.67K | $233.38K | $239.39K | $266.50K | $488.95K | $343.07K | $260.00K | $1.40M | $930.35K | $1.21M | $683.26K | $881.57K | $466.98K | $540.54K | $1.07M | $911.38K | $877.19K |
| Total Current Assets | $29.71M | $31.65M | $31.83M | $33.48M | $4.74M | $6.98M | $9.02M | $5.62M | $7.68M | $6.62M | $4.38M | $6.55M | $8.99M | $11.87M | $4.42M | $6.99M | $1.81M | $3.50M | $5.20M | $6.39M |
| Property Plant Equipment Net | $62.40K | $135.25K | $145.81K | $107.22K | $114.95K | $57.34K | $95.10K | $135.85K | $172.17K | $206.65K | $238.48K | $225.61K | $283.41K | $338.05K | $391.69K | $326.99K | $30.57K | $11.25K | $13.64K | $16.03K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.48M | $3.48M | $3.48M | $3.48M | $1.53M | $1.53M | $1.53M |
| Intangible Assets | $6.69M | $6.69M | $8.80M | $8.81M | $8.81M | $8.82M | $10.73M | $10.74M | $10.74M | $10.75M | $10.76M | $10.76M | $8.70M | $9.71M | $9.72M | $9.72M | $9.73M | $4.11M | $4.12M | $4.12M |
| Goodwill and Intangible Assets | $6.69M | $6.69M | $8.80M | $8.81M | $8.81M | $8.82M | $10.73M | $10.74M | $10.74M | $10.75M | $10.76M | $10.76M | $8.70M | $13.20M | $13.20M | $13.21M | $13.21M | $5.64M | $5.64M | $5.65M |
| Long Term Investments | $- | $- | $4.18K | $4.08K | $4.27K | $4.03K | $4.15K | $4.18K | $49.26K | $49.04K | $49.31K | $45.00K | $45.00K | $45.00K | $45.00K | $45.00K | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $-1 | $-4.03K | $-4.15K | $-4.18K | $-49.26K | $-49.04K | $-49.31K | $-45.00K | $-45.00K | $-45.00K | $-45.00K | $-45.00K | $- | $- | $- | $- |
| Other Non-Current Assets | $28.97K | $34.37K | $32.12K | $39.41K | $40.77K | $36.03K | $36.52K | $36.85K | $82.26K | $82.06K | $88.67K | $98.82K | $87.96K | $89.25K | $90.92K | $94.00K | $102.07K | $98.03K | $111.34K | $126.02K |
| Total Non-Current Assets | $6.78M | $6.86M | $8.98M | $8.96M | $8.97M | $8.91M | $10.86M | $10.91M | $11.00M | $11.04M | $11.08M | $11.09M | $9.07M | $13.62M | $13.68M | $13.63M | $13.35M | $5.75M | $5.77M | $5.79M |
| Other Assets | $- | $- | $1 | $- | $1 | $-0 | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $36.48M | $38.51M | $40.81M | $42.44M | $13.71M | $15.90M | $19.88M | $16.53M | $18.68M | $17.66M | $15.46M | $17.64M | $18.06M | $25.49M | $18.10M | $20.62M | $15.16M | $9.25M | $10.97M | $12.19M |
| Account Payables | $415.59K | $660.41K | $268.64K | $323.06K | $206.26K | $125.41K | $131.32K | $587.47K | $1.01M | $749.19K | $785.77K | $302.26K | $160.62K | $424.89K | $292.32K | $457.35K | $434.76K | $59.53K | $94.30K | $158.03K |
| Short Term Debt | $23.36K | $33.45K | $84.25K | $47.85K | $94.14K | $37.45K | $78.02K | $146.58K | $105.78K | $262.96K | $275.34K | $184.63K | $237.69K | $289.48K | $340.11K | $165.58K | $96.61K | $123.22K | $205.16K | $290.13K |
| Tax Payables | $2.33M | $150.00K | $100.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $100.00K | $- | $- | $1.46M | $1.40M | $- | $- | $- | $1.63M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $3.24M | $2.68M | $1.20M | $1.22M | $1.33M | $1.94M | $1.67M | $1.42M | $2.16M | $1.98M | $1.80M | $2.03M | $1.21M | $1.24M | $804.01K | $802.67K | $1.24M | $747.44K | $516.29K | $346.02K |
| Total Current Liabilities | $6.01M | $3.53M | $1.66M | $1.59M | $1.63M | $2.10M | $1.88M | $2.16M | $3.27M | $2.99M | $2.86M | $2.52M | $1.61M | $1.96M | $1.44M | $1.43M | $1.77M | $930.19K | $815.74K | $794.17K |
| Long Term Debt | $33.81K | $39.19K | $40.20K | $46.45K | $59.82K | $- | $- | $- | $- | $4.76K | $28.14K | $65.99K | $90.57K | $114.47K | $137.96K | $438.13K | $313.81K | $278.19K | $278.19K | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $490.69K | $779.44K | $779.44K | $779.44K | $779.44K | $689.12K | $689.12K | $689.12K | $689.12K | $802.13K | $802.13K | $802.13K | $614.44K | $728.93K | $728.93K | $728.93K | $728.93K | $365.36K | $365.36K | $365.36K |
| Other Non-Current Liabilities | $4.19M | $4.13M | $5.24M | $5.12M | $5.13M | $5.00M | $3.67M | $3.53M | $3.31M | $3.34M | $3.01M | $2.99M | $3.85M | $5.34M | $5.34M | $5.34M | $5.34M | $1.71M | $1.71M | $1.71M |
| Total Non-Current Liabilities | $4.72M | $4.95M | $6.06M | $5.94M | $5.97M | $5.69M | $4.36M | $4.22M | $4.00M | $4.15M | $3.84M | $3.86M | $7.22M | $6.19M | $6.21M | $6.51M | $6.39M | $2.35M | $2.35M | $2.08M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $10.72M | $8.48M | $7.71M | $7.54M | $7.60M | $7.79M | $6.24M | $6.37M | $7.27M | $7.14M | $6.70M | $6.38M | $8.83M | $8.15M | $7.65M | $7.94M | $8.16M | $3.28M | $3.17M | $2.87M |
| Preferred Stock | $4 | $4 | $4 | $4 | $4 | $5 | $10 | $- | $- | $- | $1 | $- | $- | $- | $41 | $41 | $41 | $41 | $41 | $41 |
| Common Stock | $267.68K | $267.68K | $267.37K | $262.58K | $77.08K | $76.92K | $69.13K | $19.21K | $17.99K | $10.79K | $130.68K | $126.64K | $126.64K | $126.19K | $70.98K | $70.98K | $55.56K | $46.27K | $46.27K | $46.27K |
| Retained Earnings | $-143.38M | $-139.16M | $-135.75M | $-133.52M | $-146.98M | $-144.71M | $-138.95M | $-136.33M | $-134.46M | $-131.96M | $-126.85M | $-124.44M | $-124.73M | $-116.36M | $-113.39M | $-110.92M | $-108.34M | $-105.92M | $-103.92M | $-102.20M |
| Accumulated Other Comprehensive Income Loss | $-282.16K | $-75.21K | $-245.74K | $-264.37K | $-182.80K | $-266.17K | $-225.86K | $-215.41K | $-182.74K | $-263.40K | $-224.86K | $-58.59K | $-86.43K | $-59.87K | $-15.14K | $9.67K | $-802 | $122.52K | $139.63K | $139.65K |
| Other Total Stockholders Equity | $169.16M | $169.00M | $168.83M | $168.43M | $153.19M | $153.00M | $152.74M | $146.68M | $146.04M | $142.74M | $135.70M | $135.63M | $135.42M | $133.64M | $123.79M | $123.52M | $115.28M | $111.72M | $111.53M | $111.33M |
| Total Stockholders Equity | $25.76M | $30.03M | $33.10M | $34.90M | $6.11M | $8.10M | $13.64M | $10.16M | $11.41M | $10.52M | $8.76M | $11.26M | $9.22M | $17.35M | $10.45M | $12.69M | $7.00M | $5.96M | $7.80M | $9.32M |
| Total Equity | $25.76M | $30.03M | $33.10M | $34.90M | $6.11M | $8.10M | $13.64M | $10.16M | $11.41M | $10.52M | $8.76M | $11.26M | $9.22M | $17.35M | $10.45M | $12.69M | $7.00M | $5.96M | $7.80M | $9.32M |
| Total Liabilities and Stockholders Equity | $36.48M | $38.51M | $40.81M | $42.44M | $13.71M | $15.90M | $19.88M | $16.53M | $18.68M | $17.66M | $15.46M | $17.64M | $18.06M | $25.49M | $18.10M | $20.62M | $15.16M | $9.25M | $10.97M | $12.19M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $36.48M | $38.51M | $40.81M | $42.44M | $13.71M | $15.90M | $19.88M | $16.53M | $18.68M | $17.66M | $15.46M | $17.64M | $18.06M | $25.49M | $18.10M | $20.62M | $15.16M | $9.25M | $10.97M | $12.19M |
| Total Investments | $23.00M | $23.40M | $21.25M | $4.08K | $4.27K | $4.03K | $4.15K | $4.18K | $49.26K | $49.04K | $49.31K | $45.00K | $45.00K | $45.00K | $45.00K | $45.00K | $- | $- | $- | $- |
| Total Debt | $57.17K | $72.64K | $82.32K | $94.30K | $106.89K | $18.73K | $39.01K | $73.29K | $105.78K | $136.25K | $165.81K | $158.31K | $209.41K | $259.22K | $308.01K | $520.92K | $362.12K | $339.80K | $380.77K | $145.06K |
| Net Debt | $-3.74M | $-5.56M | $-6.49M | $-31.18M | $-2.35M | $-5.38M | $-7.91M | $-3.35M | $-5.86M | $-4.67M | $-2.26M | $-4.91M | $-7.65M | $-10.85M | $-3.36M | $-6.09M | $-823.56K | $-2.59M | $-4.31M | $-5.73M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $3.59M | $-12.51M | $-13.58M | $-16.39M | $-8.09M |
| Depreciation and Amortization | $19.20K | $62.42K | $41.61K | $45.30K | $33.40K |
| Deferred Income Tax | $-288.75K | $90.32K | $-113.01K | $-304.78K | $12.05K |
| Stock Based Compensation | $656.59K | $754.94K | $462.45K | $842.48K | $723.86K |
| Change in Working Capital | $3.67M | $-1.82M | $668.51K | $-1.04M | $-321.21K |
| Accounts Receivables | $1.03M | $- | $-872.74K | $-441.20K | $-18.96K |
| Inventory | $- | $- | $872.74K | $441.20K | $18.96K |
| Accounts Payables | $226.12K | $-808.02K | $782.46K | $-310.67K | $136.70K |
| Other Working Capital | $2.41M | $-1.01M | $-113.95K | $-725.13K | $-457.91K |
| Other Non Cash Items | $911.27K | $3.87M | $2.10M | $5.96M | $326.67K |
| Net Cash Provided by Operating Activities | $8.56M | $-9.56M | $-10.43M | $-10.89M | $-7.32M |
| Investments in Property Plant and Equipment | $-6.26K | $1 | $- | $-63.87K | $-133.79K |
| Acquisitions Net | $- | $- | $6.38K | $-93.16K | $-110.64K |
| Purchases of Investments | $-35.63M | $- | $- | $- | $- |
| Sales Maturities of Investments | $12.98M | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $6 | $0 | $-114 |
| Net Cash Used for Investing Activities | $-22.66M | $- | $6.38K | $-157.02K | $-244.44K |
| Debt Repayment | $- | $- | $- | $-212.28K | $278.19K |
| Common Stock Issued | $15.00M | $6.15M | $5.38M | $17.75M | $5.00M |
| Common Stock Repurchased | $- | $- | $-15.63K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $499.29K | $-187.92K | $3.26M | $50.00K | $-280.69K |
| Net Cash Used Provided by Financing Activities | $15.50M | $5.97M | $8.62M | $17.80M | $5.00M |
| Effect of Forex Changes on Cash | $-57.23K | $36.02K | $-85.04K | $-81.50K | $-26.93K |
| Net Change in Cash | $1.34M | $-3.55M | $-1.89M | $6.67M | $-2.59M |
| Cash at End of Period | $3.80M | $2.46M | $6.01M | $7.90M | $1.23M |
| Cash at Beginning of Period | $2.46M | $6.01M | $7.90M | $1.23M | $3.82M |
| Operating Cash Flow | $8.56M | $-9.56M | $-10.43M | $-10.89M | $-7.32M |
| Capital Expenditure | $-6.26K | $1 | $- | $-63.87K | $-133.79K |
| Free Cash Flow | $8.55M | $-9.56M | $-10.43M | $-10.95M | $-7.45M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-4.22M | $-3.41M | $-2.22M | $13.45M | $-2.27M | $-5.76M | $-2.61M | $-1.87M | $-2.50M | $-5.12M | $-2.40M | $-3.57M | $-8.38M | $-2.97M | $-2.47M | $-2.58M | $-2.42M | $-2.01M | $-1.72M | $-1.95M |
| Depreciation and Amortization | $5.91K | $2.10K | $17.88K | $16.21K | $7.93K | $11.31K | $22.48K | $10.08K | $10.29K | $10.27K | $10.28K | $10.77K | $11.04K | $11.06K | $12.60K | $10.60K | $9.06K | $8.64K | $8.64K | $7.07K |
| Deferred Income Tax | $-288.75K | $- | $- | $- | $90.32K | $1.90M | $- | $- | $-113.01K | $- | $- | $- | $-304.78K | $- | $- | $- | $12.05K | $- | $- | $- |
| Stock Based Compensation | $160.18K | $171.18K | $149.79K | $175.44K | $182.34K | $264.86K | $171.79K | $135.94K | $45.12K | $130.15K | $71.25K | $215.92K | $213.17K | $149.47K | $262.89K | $216.94K | $193.15K | $187.73K | $197.05K | $145.92K |
| Change in Working Capital | $-1.56M | $3.30M | $-1.73M | $-7.81K | $-606.84K | $-483.12K | $856.78K | $-1.59M | $469.95K | $222.16K | $-248.75K | $225.15K | $-778.13K | $489.06K | $-490.47K | $-256.26K | $450.11K | $29.25K | $1.83K | $-802.40K |
| Accounts Receivables | $-1.07M | $2.72M | $-1.64M | $-10.82K | $-529.11K | $-575.17K | $888.47K | $-332.29K | $301.37K | $-1.11M | $-34.55K | $-33.50K | $-106.10K | $-112.45K | $-162.94K | $-59.71K | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $1.57M | $575.17K | $-888.47K | $-1.26M | $-301.37K | $1.11M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-224.86K | $384.56K | $-58.55K | $124.97K | $40.63K | $15.01K | $-508.04K | $-355.63K | $147.31K | $-6.29K | $499.80K | $141.64K | $-300.79K | $132.57K | $-165.03K | $22.58K | $287.45K | $-34.76K | $-63.73K | $-52.26K |
| Other Working Capital | $-271.15K | $194.15K | $-27.14K | $-121.97K | $-118.36K | $-498.13K | $1.36M | $355.63K | $322.64K | $228.45K | $-714.00K | $83.51K | $-477.34K | $356.50K | $-325.44K | $-278.85K | $162.66K | $64.01K | $65.56K | $-750.13K |
| Other Non Cash Items | $3.66M | $861.79K | $1.93M | $81.52K | $13.50K | $1.54M | $177.84K | $241.70K | $-42.90K | $1.79M | $69.08K | $280.78K | $5.83M | $47.13K | $46.90K | $39.49K | $41.93K | $40.97K | $42.49K | $201.29K |
| Net Cash Provided by Operating Activities | $-2.25M | $920.06K | $-3.73M | $13.62M | $-2.58M | $-2.52M | $-1.38M | $-3.07M | $-2.13M | $-2.97M | $-2.50M | $-2.83M | $-3.41M | $-2.27M | $-2.64M | $-2.57M | $-1.71M | $-1.74M | $-1.47M | $-2.40M |
| Investments in Property Plant and Equipment | $45.03K | $- | $-51.29K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $63.87K | $- | $-5.75K | $-58.12K | $-20.08K | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $6.38K | $-93.16K | $- | $- | $- | $-110.64K | $- | $- | $- |
| Purchases of Investments | $-6.54M | $-7.80M | $-21.29M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $6.98M | $5.88M | $115.65K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $-21.17M | $- | $- | $- | $- | $- | $6.38K | $- | $- | $6.38K | $-63.87K | $- | $- | $- | $-113.72K | $- | $- | $- |
| Net Cash Used for Investing Activities | $482.68K | $-1.92M | $-21.22M | $- | $-236 | $- | $- | $- | $6.38K | $1 | $- | $6.38K | $-93.16K | $- | $-5.75K | $-58.12K | $-244.44K | $-498.69K | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $278.19K | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-15.50M | $-1.14K | $15.00M | $-813.32K | $-813.32K | $6.75M | $214.68K | $- | $5.88M | $- | $- | $1.00M | $9.76M | $- | $7.99M | $- | $498.69K | $- | $4.50M |
| Common Stock Repurchased | $- | $- | $1.19M | $-1.19M | $- | $- | $- | $- | $-15.63K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $15.00M | $- | $-939.53K | $1.44M | $326.90K | $813.32K | $-813.32K | $298.50K | $3.26M | $-505.02K | $- | $- | $-1.00M | $- | $-278.19K | $50.00K | $218.00K | $- | $278.19K | $- |
| Net Cash Used Provided by Financing Activities | $- | $- | $250.52K | $15.25M | $-486.42K | $- | $5.94M | $513.17K | $3.24M | $5.38M | $- | $- | $278.19K | $9.76M | $-278.19K | $8.04M | $218.00K | $498.69K | $278.19K | $4.50M |
| Effect of Forex Changes on Cash | $-75.48K | $62.30K | $6.98K | $-51.02K | $122.18K | $-30.17K | $-28.84K | $-27.14K | $48.96K | $-36.47K | $-136.21K | $38.67K | $-27.13K | $-42.54K | $-25.96K | $14.12K | $-9.77K | $-17.32K | $-119 | $280 |
| Net Change in Cash | $-1.85M | $-938.03K | $-24.70M | $28.82M | $-2.95M | $-2.55M | $4.53M | $-2.58M | $1.16M | $2.37M | $-2.64M | $-2.79M | $-3.25M | $7.44M | $-2.95M | $5.42M | $-1.75M | $-1.76M | $-1.19M | $2.10M |
| Cash at End of Period | $3.80M | $5.64M | $6.58M | $31.28M | $2.45M | $5.40M | $7.96M | $3.43M | $6.01M | $4.85M | $2.48M | $5.11M | $7.90M | $11.15M | $3.71M | $6.66M | $1.23M | $2.98M | $4.73M | $5.92M |
| Cash at Beginning of Period | $5.64M | $6.58M | $31.28M | $2.45M | $5.40M | $7.96M | $3.43M | $6.01M | $4.85M | $2.48M | $5.11M | $7.90M | $11.15M | $3.71M | $6.66M | $1.23M | $2.98M | $4.73M | $5.92M | $3.82M |
| Operating Cash Flow | $-2.25M | $920.06K | $-3.73M | $13.62M | $-2.58M | $-2.52M | $-1.38M | $-3.07M | $-2.13M | $-2.97M | $-2.50M | $-2.83M | $-3.41M | $-2.27M | $-2.64M | $-2.57M | $-1.71M | $-1.74M | $-1.47M | $-2.40M |
| Capital Expenditure | $45.03K | $- | $-51.29K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $63.87K | $- | $-5.75K | $-58.12K | $-20.08K | $- | $- | $- |
| Free Cash Flow | $-2.21M | $920.06K | $-3.78M | $13.62M | $-2.58M | $-2.52M | $-1.38M | $-3.07M | $-2.13M | $-2.97M | $-2.50M | $-2.83M | $-3.35M | $-2.27M | $-2.64M | $-2.63M | $-1.73M | $-1.74M | $-1.47M | $-2.40M |
Kiora Pharmaceuticals Dividends
Explore Kiora Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Kiora Pharmaceuticals News
Read the latest news about Kiora Pharmaceuticals, including recent articles, headlines, and updates.
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO, Brian M.
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027
Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key fourth quarter and 2025 year-to-date corporate highlights include: Received approval to initiate KLARITY, a Phase 2 trial of KIO-104 for the treatment retinal inflammation.
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
Encinitas, California--(Newsfile Corp. - March 12, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO-104 in a proliferative vitreoretinopathy (PVR) model was accepted for poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, UT, May 4-8, 2025. The findings support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
Encinitas, California--(Newsfile Corp. - February 13, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter patent (US-12209073-B2) on a specific crystalline form, or polymorph, of KIO-104. KIO-104 is a novel, non-steroidal anti-inflammatory, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Encinitas, California--(Newsfile Corp. - February 11, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients with retinal macular edema, a condition where build-up of fluid behind part of the retina can be associated with adverse vision changes. KIO-104 is a potent, locally delivered small molecule being developed as an alternative to steroids or systemic anti-inflammatory drugs, both of which have known shortcomings.
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key third quarter and recent corporate highlights include: Investigational new drug application approval to initiate ABACUS-2, the Phase 2 study of KIO-301, a novel molecular photoswitch, for the treatment of retinitis pigmentosa.
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa
Encinitas, California--(Newsfile Corp. - October 29, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Phase 2 clinical trial to investigate KIO-301 for vision restoration in patients with retinitis pigmentosa. The ABACUS-2 trial will be a 36 patient, multi-center, double-masked, randomized, controlled, multiple dose study enrolling patients with ultra-low vision or no light perception regardless of their underlying gene mutation associated with retinitis pigmentosa.
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
Encinitas, California--(Newsfile Corp. - September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences. The presentations will be accessible live and on-demand for 90 days from our IR homepage (ir.kiorapharma.com).
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
Encinitas, California--(Newsfile Corp. - August 9, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces second quarter 2024 financial results and provides an update on its pipeline of therapeutics for the treatment of retinal diseases. During the quarter, Kiora finalized the trial design for the Phase 2 study (ABACUS-2) of KIO-301, a novel molecular photoswitch, for the treatment of retinitis pigmentosa through our partnership with Théa Open Innovation (TOI).
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies
Encinitas, California--(Newsfile Corp. - July 30, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has received Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of a group of inherited retinal diseases (IRDs) that include retinitis pigmentosa (RP), choroideremia and more. The broad designation covers KIO-301, a small molecule photoswitch, for the treatment of non-syndromic rod-dominant retinal dystrophies.
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation
Encinitas, California--(Newsfile Corp. - July 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), today announced that Eric Daniels, M.D., Chief Development Officer, will present at the Jones Trading Healthcare Seaside Summit on Monday, July 15 at 6:15 pm Eastern Time (3:15 PM Pacific Time).
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
Ken Gayron to Step Down as a Member of the Company's Board Encinitas, California--(Newsfile Corp. - July 1, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company's Board of Directors. Ms. Walters-Hoffert is a seasoned biotech executive bringing decades of experience in strategic development, governance, finance and capital markets to the Company's Board.
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
Encinitas, California--(Newsfile Corp. - June 25, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon at Bay Area Retina Associates (BARA) to its Scientific Advisory Board.
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024 Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025 Ended Q1 2024 with $31.3 million in cash and cash equivalents, providing an expected runway of more than two years Encinitas, California--(Newsfile Corp. - May 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces first quarter 2024 financial results and updates on its development pipeline of treatments for retinal disease. "Our balance sheet and strategic partnership with Théa Open Innovation (TOI) put us in a strong position to advance our two retinal programs, KIO-301 and KIO-104, into mid-stage clinical trials," said Brian M.
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
Encinitas, California--(Newsfile Corp. - May 8, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at The Citizens JMP Life Sciences Conference on Tuesday May 14th, 2024 at 1:00 pm EDT. Kiora's presentations can be accessed live from the homepage of the investor relations section on Kiora's website (ir.kiorapharma.com) and will be available for replay for 90 days on the investor relations "events" page.
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa
Previously released ABACUS-1 clinical trial results reported KIO-301, a small molecule photoswitch, is safe, tolerable, and improved vision in patients with late-stage retinitis pigmentosa. Additional analysis of functional MRI data demonstrated a statistically significant increase in neural activity over baseline within the brain's visual processing center.
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
Encinitas, California--(Newsfile Corp. - April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating functional vision assessments for patients with profound blindness. Functional vision assessments are task-oriented challenges designed to mimic real-world environments.
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
Encinitas, California--(Newsfile Corp. - April 5, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentations from two upcoming investor conferences. Kiora will present at The 23rd Annual Needham Virtual Healthcare Conference on April 11th, at 10:15 am EDT.
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, WA, May 5-9, 2024. The additional data includes quantitative evaluation of the functional MRI measures.
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2023 financial results and provided an update on its retinal disease development pipeline. The Company's major initiatives planned for 2024 are to initiate Phase 2 clinical development of KIO-301, a small molecule photoswitch, for the treatment of inherited retinal diseases, starting with retinitis pigmentosa (RP); and further development of KIO-104, an intravitreal, anti-inflammatory for treatment of non-infectious uveitis.
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced the publication of results from a Phase 1 double-masked study of KIO-101, a potent, non-steroidal anti-inflammatory agent. KIO-101 contains the same active molecule as KIO-104, which belongs to a family of potent anti-inflammatory agents, The study showed that a 12-day treatment of KIO-101 topically at multiple doses was well tolerated in healthy volunteers and patients with inflammation of the eye.
Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today?
Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is heading higher on Thursday after the clinical-stage specialty pharmaceutical company announced a $45 million private placement. According to a press release from Kiora Pharmaceuticals, the company has entered into a financing agreement with healthcare-focused institutional investors.
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
$15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million in total gross proceeds Encinitas, California--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics to improve sight in patients with severe vision loss due to inherited or age-related orphan retinal diseases, today announced that it has entered into a securities purchase agreement with healthcare focused institutional investor(s) to raise up to approximately $45 million in gross proceeds, including initial upfront funding of $15 million and up to an additional approximately $30 million upon exercise of accompanying warrants at the election of the investors. The financing includes participation from new healthcare-dedicated investors, including ADAR1 Capital Management, Nantahala Capital Management, Rosalind Advisors, Stonepine Capital Management, and Velan Capital, among others.
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties
Kiora to webcast investor conference call at 5:30 pm today; details below Encinitas, California and Clermont-Ferrand, France--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotech company developing treatments for orphan retinal diseases, today announced that it has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI), a sister company of the global ophthalmic specialty company Laboratoires Théa (Théa). Under the agreement, Kiora granted TOI exclusive worldwide development and commercialization rights, excluding Asia, to KIO-301 for the treatment of degenerative retinal diseases.
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa
Encinitas, California--(Newsfile Corp. - November 9, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its third quarter 2023 financial results and is providing an update on its plans to advance clinical development of KIO-301 for other inherited retinal diseases. On November 4, 2023, Kiora reported results from the ABACUS-1 study, a Phase 1b first-in-human clinical trial of the Company's molecular photoswitch, KIO-301, in patients with late-stage retinitis pigmentosa (RP).
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa
Topline Phase I/II First-in-Human Results Presented at AAO 2023 Significant improvement in visual field, in concordance with trended improvements in visual acuity and functional vision Functional MRI demonstrates increased brain activity in visual cortex Novel small molecule photoswitch is safe and tolerable Company presentation available on IR website (ir.kiorapharma.com) Encinitas, California--(Newsfile Corp. - November 4, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced topline results of a Phase I/II clinical trial demonstrating proof-of-concept that KIO-301, the company's first-in-class small molecule, has the potential to meaningfully improve vision in patients with Retinitis Pigmentosa (RP) who are living with ultra-low vision or complete blindness. The ABACUS study is a first-in-human, open-label, multi-site, single dose-escalating clinical trial for Kiora's intravitreal (IVT) molecular photoswitch.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for KPRX.